Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:07:52 EDT Sun 06 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Z:BMY
- BRISTOL-MYERS SQUIBB CO -
http://www.bristolmyers.com
21:07:52 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
BMY
- Z
0.1
46.85
·
47.25
0.1
46.92
-0.065
-0.1
7,024.1
47.21
47.265
46.695
63.33 39.35
Jul 03
Jun 26
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - All 0 today
More trades...
Time ET
Ex
Price
Change
Volume
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-06-26 22:05
U:BMY
News Release
200
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
2025-06-17 16:16
U:BMY
News Release
200
Bristol Myers Squibb Announces Dividend
2025-06-16 06:59
U:BMY
News Release
200
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
2025-06-12 06:59
U:BMY
News Release
200
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
2025-06-12 06:45
U:BMY
News Release
200
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
2025-06-11 06:59
U:BMY
News Release
200
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
2025-06-10 17:55
U:BMY
News Release
200
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royaltie
2025-06-06 09:45
U:BMY
News Release
200
Markey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success
2025-06-02 06:45
U:BMY
News Release
200
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
2025-05-28 06:59
U:BMY
News Release
200
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-28 06:55
U:BMY
News Release
200
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(TM) (nivolumab) Across Multiple Solid Tumor Indications
2025-05-22 17:05
U:BMY
News Release
200
Bristol Myers Squibb to Present Data at ASCO(TM) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
2025-05-21 06:59
U:BMY
News Release
200
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
2025-05-16 06:59
U:BMY
News Release
200
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(TM) (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression >=1%
2025-05-07 09:47
U:BMY
News Release
200
Improving Access to Care by Strengthening Local Health System Capacity
2025-05-06 06:59
U:BMY
News Release
200
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
2025-04-24 06:59
U:BMY
News Release
200
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
2025-04-22 16:15
U:BMY
News Release
200
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
2025-04-17 20:21
U:BMY
News Release
200
U.S. Food and Drug Administration Updates CAMZYOS(TM) (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
2025-04-14 16:15
U:BMY
News Release
200
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial